Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer

BACKGROUND: Ovarian cancer has long been known to be the deadliest cancer associated with the female reproductive system. More than 15% of ovarian cancer patients have a defective BRCA-mediated homologous recombination repair pathway that can be therapeutically targeted with PARP inhibitors (PARPi),...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Shicheng, Green, Allen, Brown, Needa, Robinson, Alexis, Senat, Merline, Testino, Bryanna, Dinulescu, Daniela M., Sridhar, Srinivas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10203577/
https://www.ncbi.nlm.nih.gov/pubmed/37228496
http://dx.doi.org/10.3389/fonc.2023.1175617

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10203577/
https://www.ncbi.nlm.nih.gov/pubmed/37228496
http://dx.doi.org/10.3389/fonc.2023.1175617

Ejemplares similares